New dose strategy aims to cut bleeding in cancer patients on blood thinners
NCT ID NCT06886516
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a specially adjusted dose of the blood thinner apixaban can safely treat blood clots in cancer patients who also have low platelet counts. About 30 adults with active cancer and a recent clot will receive the adjusted dose. The goal is to see if this approach reduces bleeding while still preventing new clots.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEEP VEIN THROMBOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a platelet-boosting drug shorten recovery after stem cell transplants?
- Simple 5-Step nursing plan could slash deadly clot risk after hip surgery
- Cord blood cells aim to speed platelet recovery in transplant patients
- Timing of blood thinners after childbirth bleeding may prevent clots without causing more harm
- Platelet transfusions may influence blood vessel health in critically ill patients
- New drug strategy may reduce blood transfusions after organ transplants